WT-161

Alternative_name

(E)-8-(2-(4-(Diphenylamino)benzylidene)hydrazinyl)-N-hydroxy-8-oxooctanamide
Description

WT-161 is a potent, selective, and bioavailable HDAC6 (histone deacetylase-6) inhibitor (IC₅₀ 0.40 nM). It is selective for HDAC6 over HDAC3 (IC₅₀ = 51.61 nM) and induces α-tubulin acetylation, an HDAC6-dependent process, with minimal effect on global lysine acetylation. WT161 inhibits growth of patient-derived multiple myeloma cell lines with IC₅₀ values ranging from 1.5 to 4.7 μM. WT161 enhances the cytotoxicity of bortezomib (Cat. No. 1846) and carfilzomib (Cat. No. 2385) against patient-derived multiple myeloma cells.
CAS Number

1206731-57-8
Structure Available

Yes
Salt Form

No
Molecular Formula

C₂₇H₃₀N₄O₃
Molecular Weight

458.56
Cell Permeable

Yes
Purity

≥98% by HPLC
Solubilities

DMSO
Handling

Protect from air and light
Tag Line

A potent, selective, and bioavailable HDAC6 (histone deacetylase-6) inhibitor
Storage Condition

-20°C
Shipping Condition

gel pack
Shelf Life

36 months
PubChem CID

44601455
PubChem CID Link
SMILES

C1=CC=C(C=C1)N(C2=CC=CC=C2)C3=CC=C(C=C3)C=NNC(=O)CCCCCCC(=O)NO
InChi

InChI=1S/C27H30N4O3/c32-26(15-9-1-2-10-16-27(33)30-34)29-28-21-22-17-19-25(20-18-22)31(23-11-5-3-6-12-23)24-13-7-4-8-14-24/h3-8,11-14,17-21,34H,1-2,9-10,15-16H2,(H,29,32)(H,30,33)/b28-21+
InChi Key

KXWWYFKVBFUVIZ-SGWCAAJKSA-N
Data Sheet Link
MSDS Available

Yes